Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical has secured an exclusive license to commercialize Formycon's Eylea® biosimilar, FYB203/AHZANTIVE®, in the Asia-Pacific region. The agreement includes countries such as Indonesia, Malaysia, Singapore, and Taiwan. Formycon will supply the finished product and participate in earnings through royalties and milestone payments.

Lotus, a multinational company with a strong presence in Asia, aims to enhance healthcare access with this strategic partnership. The U.S. FDA approved FYB203 in June 2024, followed by the European Commission in January 2025. The biosimilar targets severe retinal diseases by inhibiting VEGF, responsible for excessive blood vessel formation in the retina.